Analysts Offer Insights on Healthcare Companies: Baxter International (BAX) and Capricor Therapeutics (CAPR)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Baxter International (BAX) and Capricor Therapeutics (CAPR).
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Baxter International (BAX)
In a report issued on May 8, Steven Silver from Argus Research maintained a Hold rating on Baxter International. The company’s shares closed last Monday at $17.55.
According to TipRanks.com, Silver is ranked #4105 out of 12243 analysts.
Baxter International has an analyst consensus of Hold, with a price target consensus of $20.09, representing an 11.9% upside. In a report issued on April 30, TipRanks – Google also upgraded the stock to Hold with a $16.00 price target.
See the top stocks recommended by analysts >>
Capricor Therapeutics (CAPR)
Roth MKM analyst Boobalan Pachaiyappan maintained a Buy rating on Capricor Therapeutics today and set a price target of $43.00. The company’s shares closed last Monday at $31.89.
According to TipRanks.com, Pachaiyappan is a 3-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Capricor Therapeutics with a $55.13 average price target, which is an 81.9% upside from current levels. In a report issued on May 8, Oppenheimer also maintained a Buy rating on the stock with a $54.00 price target.
Read More on BAX:
